





$\mathsf{SYMBYAX}^{\textcircled{B}}$ (olanzapine and fluoxetine HCl capsules)

INDICATIONS AND USAGE BYAX is indicated for the treatment of depressive episodes associated with bipolar disorder. The of SYMBYAX was established in 2 identically designed, 8-week, randomized, double-blind SYMBYAX is indicated for the trea clinical studies.

Unlike with unipolar depression, there are no established guidelines for the length of time patients with bipolar disorder experiencing a major depressive episode should be treated with agents containing antidepressant drugs.

The effectiveness of SYMBYAX for maintaining antidepressant response in this patient population beyond 8 weeks has not been established in controlled clinical studies. Physicians who elect to use SYMBYAX for extended periods should periodically reevaluate the benefits and long-term risks of the drug for the individual patient.

SYMBYAX for extended periods should periodically reevaluate the benefits and long-term hisks of the drug for the individual patient. CONTRAINDICATIONS Hypersensitivity — SYMBYAX is contraindicated in patients with a known hypersensitivity to the product or any component of the product. Monoamine Oxidase Inhibitors (MAOI) — There have been reports of serious, sometimes fatal reactions (including hyperthemia, rigidit, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirum and coma) in patients receiving flucxatine in combination with an MAOI, and in patients who have recently discontinued flucxatine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, SYMBYAX should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Since flucxetine and its major metabolite have very long elimination half-lives, at least 5 weeks [perhaps longer, especially if flucxetine has been prescribed chronically and/or at higher doses (see CLINICAL PHARMACOLOGY, Accumulation and slow elimination)] should be allowed after stopping SYMBYAX before starting an MAOI. **Pimozide** — Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS). **Thioridazine** — Thioridazine should not be administered with SYMBYAX or administered within a minimum of 5 weeks after discontinuation of SYMBYAX (see WARNINGS, Thioridazine). **WARNINGS**

Inioridazine — Inioridazine should not be administered with SYMBYAX or administered within a minimum of 5 weeks after discontinuation of SYMBYAX (see WARNINGS, Thioridazine). WARNINGS Clinical Worsening and Suicide Risk — Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. There has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Nooled analyses of short-term placebo-controlled trials of 9 antidepressant drugs (SRIs and others) in children and adolescents with MDD, OCD, or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients neceiving antidepressant was 4%, twice the placebo risk of 2%. There was considerable variation in risk among drugs, but a tendency toward an increase for almost all drugs studied. The risk of suicidality was most consistently obsenved in the MDD trials, but there were signals of risk arising from some trials in other psychiatric indications (obsessive compulsive disorder and social anxiety disorder) as well. **No suicides occurred in amy of these trials**. It is unknown whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months. It is also unknown whether the suicidality risk extends to ad

unknown whether the suicidality risk extends to adults. All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may be appropriate between face-to-face visits. Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

es or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggress impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidipensants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms and represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suidality or symptoms that might be precursors to worsening depression or suidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is

If the decision has been made to discontinue treatment, medication should be fapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION, Discontinuation of Treatment with SYMBYAX, for a description of the risks of discontinuation of SYMBYAX). Families and caregivers of pediatric patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for SYMBYAX, should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. Families and caregivers of patients approved for use in treating any indications in the pediatric population.

Screening Patients for Bipolar Disorder — A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant represent source source sources and source in the ownership that is making ineditient with an anticouple source patients with depressive symptoms should be adequately screened to determine if they are at risk to bipolar disorder; such screening should include a detailed psychiatric history, including a family history o suicide, bipolar disorder, and depression. It should be noted that SYMBYAX is approved for use in treating

Increased Mortality in Elderly Patients with Dementia-Related Psychosis — Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. SYMBYAX (olanzapine and fluoxetine HCI) is not approved for the treatment of patients with dementia-related psychosis (see BOX WARNING).

In olanzapine placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively)

Cerebrovascular Adverse Events (CVAE), Including Stroke, in Elderly Patients with Dementia-Related Psychosis — Cerebrovascular adverse events (e.g., stroke, transient isohemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.

approved for the treatment of patients with dementian-related psycholos. Hyperglycemia and Diabetes Mellitus — Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypica antipsychotics, including olanzapine alone, as well as olanzapine taken concomitantly with fluxetine An payments of the relationship between atypical antipsychotic use and jucose abnormatistis is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completately understood. However, enidemiolocical studies, surneate an increased risk ad od. Ho treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with the atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polydipsia, polydipsia, adveakmess. Patients who develop symptoms of hyperglycemia activity polydipsia, adveakmess. Patients who develop symptoms of hyperglycemia function polydipsia, polydipsi

SYMBYAX® (olanzapine and fluoxetine HCl capsules)

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer of this type. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. As is common with evaluate that increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogeneity studies conducted in mice and rats (see Carcinogenesis). However, neither clinical studies nor epidemiologic studies have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered to limited to be conclusive.

drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive. **Hyponatremia** — Hyponatremia has been observed in SYMBYAX premarketing clinical studies. In controlled trials, no SYMBYAX-treated patients had a treatment-emergent serum sodium below 130 mmol/L; however, a lowering of serum sodium below the reference range occurred at an incidence of 2% (10/500) of these SYMBYAX-treated patients had a treatment-emergent serum solium below 130 mmol/L; however, a lowering of serum sodium below the reference range occurred at an incidence of 2% (10/500) of these SYMBYAX-treated patients had a treatment-emergent serum sodium below 130 mmol/L. Cases of hyponatremia (some with serum sodium lower than 110 mmol/L) have been reported with fluoxetine. The hyponatremia appeared to be reversible when fluoxetine was discontinued. Although these cases were complex with varying possible etiologies, some were possibly due to the syndrome of inappropriate antiduretic hormone secretion (SIADH). The majority of these occurrences have been in older patients and in patients taking diuretics or who were otherwise volume depleted. In two 6-week controlled studies in patients 260 years of age, 10 of 322 fluoxetine patients and 6 of 327 placebo recipients had a lowering of serum sodium below the reference range; this difference was not statistically significant. The

studies in patients 2:o0 years or age, 10 of 22 indoxetine patients and 6 of 22 iplacedo recipients had a lowering of serum sodium below the reference range; this difference was not statistically significant. The lowest observed concentration was 129 mmol/L. The observed decreases were not clinically significant. The Seizures — Seizures occurred in 0.2% (4/2066) of SYMBYAX-treated patients during open-label premarketing clinical studies. No seizures occurred in the premarketing controlled SYMBYAX studies. Seizures have also been reported with both olarazpine and fluxetine monotherapy. Therefore, SYMBYAX studies should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 265 years of age. 265 years of age

26b years of age. Transaminase Elevations — As with olanzapine, asymptomatic elevations of hepatic transaminases [ALT (SGPT), AST (SGOT), and GGT] and alkaline phosphatase have been observed with SYMBYAX. In the SYMBYAX-controlled database, ALT (SGPT) elevations (25 times the upper limit of the normal range) were observed in 6.3% (21/495) of patients exposed to SYMBYAX compared with 0.5% (2/384) of the placebo patients and 4.5% (25/560) of olanzapine-treated patients. The difference between SYMBYAX and placebo was statistically significant. None of these 31 SYMBYAX-treated patients experienced jaundice and three had transient elevations >200 IU/L.

three had transient elevations >200 IU/L. In olanzapine placebo-controlled studies, clinically significant ALT (SGPT) elevations (>3 times the upper limit of the normal range) were observed in 2% (6/243) of patients exposed to olanzapine compared with 0% (0/15) of the placebo patients. None of these patients exported to almost entrol the separation of the separation of the placebo patients. None of these patients experienced jaundice. In 2 of these patients, liver enzymes decreased toward normal despite continued treatment, and in 2 others, enzymes decreased upon discontinuation of olanzapine. In the remaining 2 patients, 1, seropositive for hepatitis C, had persistent enzyme elevations for 4 months after discontinuation, and the other had insufficient follow-up to determine if enzymes normalized.

erzymes normalized. Within the larger olanzapine premarketing database of about 2400 patients with baseline SGPT ≤90 IU/L, the incidence of SGPT elevation to >200 IU/L was 2% (50/2381). Again, none of these patients experienced jaundice or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued. Among all 2500 patients in olanzapine clinical studies, approximately 1% (23/2500) discontinued treatment due to transaminase increases.

approximately 1% (23/2500) discontinued treatment due to transaminase increases. Caution should be exercised in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. Periodic assessment of transaminases is recommended in patients with significant hepatot studies, the mean weight increase for SYMBYAX-treated patients was statistically significantly greater than placebo-treated (3.6 kg vs -0.3 kg) and fluoxetine-treated patients (3.6 kg vs 3.0 kg). Fourteen percent of SYMBYAX-treated patients for of anzapine-treated patients (3.6 kg vs 3.0 kg). Fourteen percent of SYMBYAX-treated patients meriterion for having gained >10% of their baseline weight. This was statistically significantly greater than placebo-treated (<1%) and fluoxetine-treated patients (<1%) but was not statistically significantly greater than placebo-treated (<1%) and fluoxetine-treated patients (<1%) but was not statistically significantly greater than placebo-treated (<1%) and fluoxetine-treated patients (<1%) but was not statistically significantly different than olanzapine-treated patients (11%).

than olanzapine-treated patients (11%). Use in Patients with Concomitant Illness Clinical experience with SYMBYAX in patients with concomitant systemic illnesses is limited (see CLINCAL PHARMACOLOGY, Renal Impairment and Hepatic Impairment). The following precautions for the individual components may be applicable to SYMBYAX. Olanzapine exhibits in vitro muscarinic receptor affinity. In premarketing clinical studies, SYMBYAX was associated with constipation, dry mouth, and tachycardia, all adverse events possibly related to cholinergic antagonism. Such adverse events were not often the basis for study discontinuations; SYMBYAX should be used with caution in patients with clinically significant prostatic hypertrophy, narrow angle glaucoma, a history of paralytic ileus, or related conditions.

In five placebo-controlled studies of olanzapine in elderly patients with dementia-related In five placebo-controlled studies of olanzapine in elderly patients with dementia-related psychosis (n=1184), the following treatment-emergent adverse events were reported in olanzapine-treated patients at an incidence of at least 2% and significantly greater than placebo-treated patients: falls, somolence, peripheral edema, abnormal gait, urinary incontinence, lethargy, increased weight, asthenia, pyrexia, pneumonia, dry mouth and visual hallucinations. The rate of discontinuation due to adverse events was significantly greater with olanzapine than placebo (13% vs 7%). Elderly patients with dementia-related psychosis treated with olanzapine are at an increased risk of death compared to placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis. If the prescriber elects to treat elderly patients with dementia-related psychosis, vigilance should be exercised (see BOX WARNING and WARNINGS). As with other CINS-active druns. SYMBYAX should be used with caution in elderly patients with

As with other CNS-active drugs, SYMBYAX should be used with caution in elderly patients with dementia. Olanzapine is not approved for the treatment of patients with dementia-related psychosis. If the prescriber elects to treat elderly patients with dementia-related psychosis, vigilance should be exercised (see BOX WARNING and WARNINGS).

SYMBYAX has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from clinical studies during the premarket testing.


Caution is advised when using SYMBYAX in cardiac patients and in patients with diseases or conditions that could affect hemodynamic responses (see WARNINGS, Orthostatic Hypotension). In subjects with cirrhosis of the liver, the clearances of fluoxetine and its active metabolite, norfluoxetine, were decreased, thus increasing the elimination half-lives of these substances. A lower dose of the fluoxetine-component of SYMBYAX should be used in patients with cirrhosis. Caution is advised when using SYMBYAX in patients with diseases or conditions that could affect its metabolism (see CLINICAL PHARMACOLOGY, Hepatic Impairment and DOSING AND ADMINISTRATION, Special Populations). Olanzanie and fluoxetine individual pharmacokinetics do not differ similatority in patients with renal

Olanzapine and fluoxetine individual pharmacokinetics do not differ significantly in patients with renal impairment. SYMBYAX dosing adjustment based upon renal impairment is not routinely required (see CLINCAL PHARMACOLOGY, Renal Impairment).

Information for Patients Information for Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with SYMBYAX and should counsel them in its appropriate use. A patient Medication Guide About Using Antidepressants in Children and Teenagers is available for SYMBYAX. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if these oncur while Patients should be advised of the following issues and asked to alert their prescriber if these occur while

taking SYMBYAX. Clinical Worsening and Suicide Risk — Patients, their families, and their caregivers should be


encouraged to be alert to the emergence of anxiety, agitation, panic attacks, incomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a davi-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe



corresponds to a molecular weight of 312.44. Fluxestine hydrochloride is a selective serotonin reuptake inhibitor (SSRI). The chemical designation is (±)-N-methyl-3-phenyl-3-1(α,α,α -trifluoro-p-tolyl)oxy]propylamine hydrochloride. The molecular formula is $C_{17}H_{18}F_3$ NO-HCl, which corresponds to a molecular weight of 345.79.

The chemical structures are

depressive SYMBYAX o



Olanzapine is a yellow crystalline solid, which is practically insoluble in water Fluoxetine hydrochloride is a white to off-white crystalline solid with a solubility of 14 mg/mL in water. SYMBYAX capsules are available for oral administration in the following strength combinations:

	6 mg/25 mg	6 mg/50 mg	12 mg/25 mg	12 mg/50 mg
olanzapine equivalent	6	6	12	12
fluoxetine base equivalent	25	50	25	50

sulfate, edible black ink, red iron oxide, yellow iron oxide, and/or black iron oxide. CLINICAL PHARMACOLOGY

odynamics

rnamacdoynamics Although the exact mechanism of SYMBYAX is unknown, it has been proposed that the activation of 3 monoaminergic neural systems (serotonin, norepinephrine, and dopamine) is responsible for its enhanced antidepressant effect. This is supported by animal studies in which the olanzapinefluxwetine combination Although th 3 monoamine

aniopressant effect. This is supported by animal sources in which the ordinazphaeniooxenine combination has been shown to produce synergistic increases in norepinephrine and dopamine release in the prefrontal cortex compared with either component alone, as well as increases in serotonin. Olanzapine is a psychotropic agent with high affinity binding to the following receptors: serotonin SHT_{2ACC} (Kj=4 and 11 nM, respectively), dopamine D_{1-4} (Kj=11 to 31 nM), muscarinic M_{1-5} (Kj=1.9 to 25 nM), histamine H_1 (Kj=7 nM), and adrenergic α_1 receptors (Kj=19 nM). Olanzapine binds weakly to GABA₆₄, B2D, and β-adrenergic receptors (Kj=10 nM). Fluxetine is an inhibitor of the serotonin transporter and is a weak inhibitor of the norepinephrine and dopamine transporters.

and is a weak inhibitor of the norepinephrine and dopamine transporters. Antagonism at receptors other than dopamine and \$HT_2 with similar receptor affinities may explain some of the other therapeutic and side effects of olanzapine. Olanzapine's antagonism of histamine H_1 receptors by olanzapine may explain its anticholinergic effects. The antagonism of histamine H_1 receptors by olanzapine may explain the orthostatic hypotension observed with this drug. Fluoxetine has relatively low affinity for muscarinic, α_1 -adrenergic, and histamine H_1 receptors. Pharmacokinetics

Pharmacokinetics Flucetine (administered as a 60-mg single dose or 60 mg daily for 8 days) caused a small increase in the mean maximum concentration of olanzapine (16%) following a 5-mg dose, an increase in the mean area under the curve (17%) and a small decrease in mean apparent clearance of olanzapine (16%). In another study, a similar decrease in apparent clearance of olanzapine of 14% was observed following olanzapine doses of 6 or 12 mg with concomitant fluxetine doses of 25 mg or more. The decrease in clearance reflects an increase in bioavailability. The terminal hall-life is not affected, and therefore the time to reach steady state should not be altered. The overall steady-state plasma concentrations of olanzapine and fluxetine when given as the combination in the therapeutic dose ranges were comparable with those typically attained with each of the monotherapies. The small change in olanzapine clearance, via CYP2D6 by fluxetine, a potent CYP2D6 inhibitor, and was not deemed to inically significant. Therefore, the pharmacokinetics of the individual components is expected to reasonably characterize the overall pharmacokinetics of the combination. Absorption and Bioavailability

Absorption and Bioavailability

- Following a single oral 12-mg/50-mg dose of SYMBYAX, peak plasma concentrations of STMDTAA — policy a single of all 22-ing/so-thig dose of STMDTAA, peak plasma concentrations on ofanzapine and fluxetime occur at approximately 4 and 6 hours, respectively. The effect of food on the absorption and bioavailability of SVMBYAX has not been evaluated. The bioavailability of olanzapine as Zyprexa, and the bioavailability of fluxetine given as Proze were not affected by food. It is unlikely that there would be a significant food effect on the bioavailability of SYMBYAX. **Olanzapine** — Olanzapine is well absorbed and reaches peak concentration approximately 6 hours following an oral dose. Food does not affect the rate or extent of olanzapine absorption when olanzapine is given as Zyprexa. It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized hefore reaching the systemic circulation

Olanzapine — Olanzapine is well ausorued and following an oral dose. Food does not affect the rate given as Zyprexa. It is eliminated extensively by first metabolized before reaching the systemic circulation.

Fluoxetine — Following a single oral 40-mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours. Food does not appear to affect the systemic

SYMBYAX®

(olanzapine and fluoxetine HCl capsules) WARNING

Suicidality in Children and Adolescents — Antidepressants increased the risk of suicidal hinking and behavior (suicidality) in short-term studies in children and adolescents with major lepressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of SYMBYAX or any other antidepressant in a child or adolescent must balance this risk with the linical need. Patients who are started on therapy should be observed closely for clinical vorsening, suicidality, or unusual changes in behavior. Families and caregivers should be disorder the band for alco checretic and communication with the preserver SYMBYAY is and the started started or therapy should be the started or therapy should be the started and the started or therapy should be the started at the started started or therapy should be the started at the started started a

ne given as Prozac, although it may delay its absorption by 1 to 2 hours is probably not clinically significant

Distribution SYMBYAX -

- The in vitro binding to human plasma proteins of the olanzapine/fluoxetine combination is similar to the binding of the individual compone

similar to the binding of the individual components. Olanzapine — Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L. It is 93% bound to plasma proteins over the concentration range of 7 to 1100 ng/mL, binding primarily to albumin and α₁-acid glycoprotein. Fluoxetine and other highly protein-bound drugs has not been fully evaluated (see PRECAUTIONS, Drugs tightly bound to plasma proteins).

Ingmit yound to plasma proteins). Metabolism and Elimination SYMBYAX — SYMBYAX therapy yielded steady-state concentrations of norfluoxetine similar to those seen with fluoxetine in the therapeutic dose range. Olanzapine — Olanzapine displays linear pharmacokinetics over the clinical dosing range. Its half-life ranges from 21 to 54 hours (5th to 95th percentile; mean of 30 hr), and apparent plasma clearance ranges from 12 to 47 Lhr (5th to 95th percentile; mean of 25 Lhr). Administration of olanzapine once daily leads to steady-state concentrations in about 1 week that are approximately twice the concentrations after single doses Plasma concentrations balfilf and clearance or folanzarione may usery between individuals on the

steady-state concentrations in about 1 week that are approximately twice the concentrations after single doese. Plasma concentrations, half-life, and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age (see Special Populations). Following a single oral dose of ¹⁴C-labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4⁻N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. concentration of olanzapine, and 4'-N-desmethyl olanzapine, present at steady state at 44% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed. Direct glucuronidation and CYP450-mediated oxidation are the primary metabolic pathways for olanzapine. In vitro studies suggest that CYP1A2, CYP2D6, and the flavin-containing monoxygenase system are involved in olanzapine oxidation. CYP2D6-mediated oxidation appears to be a minor metabolic pathway in vivo, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme. Fluoxetine — Fluoxetine is a racemic mixture (50/50) of *R*-fluoxetine and S-fluoxetine enantiomers. In animal models, both enantomers are specific and potent serotonin uptake inhibitors with essentially equivalent ohormacolonic activity. The S fluoxetine to support the serotonin uptake inhibitors with essentially

enantiomers are specific and potent serotonin uptake inhibitors with essentially logic activity. The S-fluoxetine enantiomer is eliminated more slowly and is the auivale predominant enantiomer present in plasma at steady state.

Fluoxetine is extensively metabolized in the liver to its only identified active metabolite, norfluoxetine, via the CYP2D6 pathway. A number of unidentified metabolites exist

In animal models, S-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine. R-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.

inactive metabolites excreted by the kidney. **Clinical Issues Related to Metabolism and Elimination** — The complexity of the metabolism of fluoxetine has several consequences that may potentially affect the clinical use of SYMBYAX. <u>Variability in metabolism</u> — A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme CYP2D6. Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants (TCAs). In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized S-fluoxetine at slower rate and thus achieved higher concentrations of S-fluoxetine. Consequently, concentrations of S-norfluoxetine at steady state were lower. The metabolizers of *R*-fluoxetine in these poor metabolizers. appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative nonsaturable pathways (non-CVP2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steady-state concentration rather than increasing without limit.

Concentration ratinet main increasing without limit. Because the metabolism of fluxestine, like that of a number of other compounds including TCAs and other selective serotonin antidepressants, involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions (see PRECAUTIONS, Drug Interactions). <u>Accumulation and slow elimination</u> — The relatively slow elimination of fluxetine (elimination half-life of the advance drug and the 5 drug entry elimination) and the action predictivity.

Accommutation and stow elimination — The relatively slow elimination of incoverine (elimination hard-net of 1 to 3 days after acute administration and 4 to 6 days after chronic administration), and its active metabolite, norfluxetine (elimination hall-life of 4 to 16 days after chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used. After 30 days of dosing at 40 mg/day, plasma concentrations of fluxetine in the range of 91 to 302 ng/mL and norfluxextine in the range of 72 to 258 ng/mL have been observed. Plasma concentrations of fluxextine were higher than those predicted by single-dose studies, because the metabolism of fluxextine is not concortional. In dose, Howaver, onpluveting anopare, I, bava, linear

concentrations on indoxetine were inginer main those predicted by single-dose studies, because the metabolism of fluoxetine is not proportional to dose. However, norfluoxetine appears to have linear pharmacokinetics. Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady-state levels after prolonged dosing are similar to levels seen at 4 to 5 weeks. The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with luvacing and unduration following the discontinuation. interact with fluoxetine and norfluoxetine following the discontinuation of fluoxe

Special Populations Geriatric — Based on the individual pharmacokinetic profiles of olanzapine and fluoxetine, the pharmacokinetics of SYMBYAX may be altered in geriatric patients. Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or odynamic sensitivity.

In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine was about 1.5 times greater in elderly subjects (>65 years of age) than in non-elderly subjects (<65 years of age).

greater in elderly subjects (>65 years of age) than in non-elderly subjects (>65 years of age). The disposition of single doses of fluoxetine in healthy elderly subjects (>65 years of age) did not differ significantly from that in younger normal subjects. However, given the long half-life and nonlinear disposition of the drug, a single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases. The effects of age upon the metabolism of fluoxetine have been investigated in 260 elderly but otherwise healthy depressed patients (>260 years of age) who received 20 mg fluoxetine for 6 weeks. Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3 ± 85.7 ng/mL at the end of 6 weeks. No unusual age-associated patiern of adverse events was observed in those elderly patients. **Renal Impairment**. The pharmacokinetics of SYMBYAX has not been studied in patients with renal impairment. However, olanzapine and fluoxetine individual pharmacokinetics do not differ significantly in patients with renal impairment. SYMBYAX dosing adjustment based upon renal impairment is not routinely required.

routinely required. Because clanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine. The pharmacokinetic characteristics of olanzapine were similar in patients with severe renal impairment and normal subjects, indicating that dosage adjustment based upon the degree of renal impairment is not required. In addition, olanzapine is not removed by dialysis. The effect of renal impairment on olanzapine metabolite elimination has not been studied.

In depressed patients on dialysis (N=12), fluoxetine administered as 20 mg once daily for 2 mon In depressed patients on darjost (W=12), indoxetine administered as 20 mg office darjo to 2 information produced steady-state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in patients with normal renal function. While the possibility exists that renally excreted metabolites of fluoxetine may accumulate to higher levels in patients with severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients. Hepatic Impairment — Based on the individual pharmacokinetic profiles of clanzapine and fluoxetine, the pharmacokinetics of SYMBYAX may be altered in patients with hepatic impairment. The lowest starting

the pharmacokinetics of SYMBYAX may be altered in patients with hepatic impairment. The lowest starting dose should be considered for patients with hepatic impairment (see PRECAUTIONS, Use in Patients with Concomitant liness and DOSAGE AND ADMINISTRATION, Special Populations).

Although the presence of lepatic impairment may be expected to reduce the clearance of olanzapine, a study of the effect of impaired liver function in subjects (N=6) with clinically significant cirrhosis (Childs-Pugh Classification A and B) revealed little effect on the pharmacokinetics of olanzapine. As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of fluoxetine. The elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of 7.6 days compared with the range of 2 to 3 days seen in subjects without liver disease; norfluoxetine elimination was also delayed, with a mean duration of 12 days for cirrhotic patients compared with the range of 7 to 9 days in normal subjects. of 7 to 9 days in normal subjects

Gender - Clearance of olanzapine is approximately 30% lower in women than in m however, no apparent differences between men and women in effectiveness or adverse modifications based on gender should not be needed.

Smoking Status — Olanzanine clearance is about 40% higher in smokers than in nonsmokers although dosage modifications are not routinely required

Race — No SYMBYAX pharmacokinetic study was conducted to investigate the effects of race. Result Race — No SYMBYAX pharmacokinetic study was conducted to investigate the effects of race. Results from an olanzapine cross-study comparison between data obtained in Japan and data obtained in the US suggest that exposure to olanzapine may be about 2-fold greater in the Japanese when equivalent doses are administered. Olanzapine clinical study safety and efficacy data, however, did not suggest clinically significant differences among Caucasian patients, patients of African descent, and a 3rd pooled category including Asian and Hispanic patients. Dosage modifications for race, therefore, are not routinely required. **Combined Effects** — The combined effects of age, smoking, and gender could lead to substantial pharmacokinetic differences in populations. The clearance of olanzapine in young smoking males, for example, may be 3 times higher than that in elderly nonsmoking females. SYMBYAX dosing modification may be necessary in patients who exhibit a combination of factors that may result in slower metabolism of the olanzapine component (see DOSAGE AND ADMINISTRATION, Special Populations). **CLINICAL STUDIES**

The dialzapine component (see DOSAGE and ADMINIOTRATION, Special Populations). CLINICAL STUDIES The efficacy of SYMBYAX for the treatment of depressive episodes associated with bipolar disorder was established in 2 identically designed, 8-week, randomized, double-bind, controlled studies of patients who met Diagnostic and Statistical Manual 4th edition (DSM-IV) oriteria for Bipolar I Disorder, Depressed utilizing flexible dosing of SYMBYAX (6/25, 6/50, or 12/50 mg/day), danzapine (5 to 20 mg/day), and placebo. These studies included patients (≥18 years of age) with or without psychotic symptoms and with or without a raid circuling ourse.

without a rapid cycling course. The primary rating instrument used to assess depressive symptoms in these studies was the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale with total scores ranging from 0 to 60. The primary outcome measure of these studies was the change from baseline to endpoint in the MADRS total score. In both studies, SYMBYAX was statistically significantly superior to both olanzapine monotherapy and placebo in reduction of the MADRS total score. The results of the studies are summarized below (Table 1).

ble 1: MADRS Total S

Mean Change from Baseline to Endpoint Baseline Mean Treatment Group Change to Endpoint Mean¹ SYMBYAX (N=40) 30 -16a Olanzapine (N=182) 32 -12

31

-10

% (0/241) in the fluoxetine group. SYMBYAX should be used with particular caution in patients with known cardiovascular disease (history myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or inditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with

Allergic Events and Rash — In SYMBYAX premarketing controlled clinical studies, the overall incidence of rash or allergic events in SYMBYAX premarketing controlled clinical studies, the overall incidence of rash or allergic events in SYMBYAX treated patients (4.6% (26/s71)) was similar to that of placebo (5.2% (25/477)). The majority of the cases of rash and/or urticaria were mild; however, three patients discontinued (one due to rash, which was moderate in severity, and two due to allergic events, one of which included face edema).

which particle version of which included face edema). In fluxeetine US clinical studies, 7% of 10.782 fluxeetine-treated patients developed various types of rashes and/or urticaria. Among the cases of rash and/or urticaria reported in premarketing clinical studies, almost a third were withdrawn from treatment because of the rash and/or systemic signs or symptoms associated with the rash. Clinical findings reported in association with rash include fever, leukocytosis, arthralgias, edema, carpal tunnel syndrome, respiratory distress, lymphadenopathy, proteinuria, and mild transaminase elevation. Most patients improved promptly with discontinuation of fluxeetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these events were reported to recover completely.

In fluxerine premarketing clinical studies, 2 patients are known to have developed a serious stemic illness. In neither patient was there an unequivocal diagnosis, but 1 was considered kocytoclastic vasculitis, and the other, a severe desquamating syndrome that was considered be a vasculitis or erythema multiforme. Other patients have had systemic syndromes sug serum sickness.

Since the introduction of fluoxetine, systemic events, possibly related to vasculitis, have developed in patients with rash. Although these events are rare, they may be serious, involving the lung, kidney, or liver. Death has been reported to occur in association with these systemic events.

Anaphylactoid events, including bronchospasm, angioedema, and urticaria alone and in combination have been reported.

Pulmonary events, including inflammatory processes of varying histopathology and/or fibrosis, have been reported rarely. These events have occurred with dyspnea as the only preceding symptom

reported rarely. These events have occurred with dyspnea as the only preceding symptom. Whether these systemic events and rash have a common underlying cause or are due to different etiologies or pathogenic processes is not known. Furthermore, a specific underlying immunologic basis for these events has not been identified. Upon the appearance of rash nor of other possible allergic phenomena for which an alternative etiology cannot be identified, SYMBYAX should be discontinued. **Neuroleptic Malignant Syndrome (NMS)** — A potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including olarzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is Ine diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy. 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If after recovering from NMS, a patient requires treatment with an antipsychotic, the patient should be carefully monitored, since recurrences of NMS have been reported.

Tardive Dyskinesia — A syndrome of potentially irreversible, involuntary, dyskinetic movements may evelop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to bevelop in patients treated wirk, sepecially elderly women, it is impossible to rely upon prevalence et to predict, at the inception of antipsychotic treatment, which patients are likely to develop the sy Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are beli increase as the duration of treatment and the total cumulative dose of antipsychotic drugs adminis the patient increase. However, the syndrome can develop, although much less commonly, after r brief treatment periods at low doses or may even arise after discontinuation of treatment.

There is no known treatment for established cases of tardive dyskinesia, although the syndrom mit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, ho name, paramy or comparing a manapyorious realiment is winnawn. Antipsystronic treatment is set now were may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

the syndrome is unknown. The incidence of dyskinetic movement in SYMBYAX-treated patients was infrequent. The mean score on the Abnormal Involuntary Movement Scale (AIMS) across clinical studies involving SYMBYAX-treated patients decreased from baseline. Nonetheless, SYMBYAX should be prescribed in a manner that is most likely to minimize the risk of tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear in a patient on SYMBYAX, drug discontinuation should be considered. However, some patients may require treatment with SYMBYAX despite the presence of the syndrome. The need for continued treatment should the appearance of the syndrome.

Thioridazine — In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators Thioridazine — In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators and a 4 5-fold of debrisoquin, a single 25-mg oral dose of thioridazine produced a 2.4-fold higher C_{max} and a 4.5-fo higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this stur suggests that drugs that inhibit CYP2D6, such as certain SSRIs, including fluxetine, will produce elevate plasma levels of thioridazine (see PRECAUTIONS).

Thioridazine administration produces a dose-related prolongation of the QT_c interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias and sudden death. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism (see CONTRAINDICATIONS, Thioridazine).

PRECAUTIONS

Concomitant Use of Olanzapine and Fluoxetine Products — SYMBYAX contains the same active ingredients that are in Zyprexa and Zyprexa Zydis (olanzapine) and in Prozac, Prozac Weekly, and Sarafem (fluoxetine HCI). Caution should be exercised when prescribing these medications concomitantly with SYMBYAX.

Saratem (fluoxetine HCI). Caution should be exercised when prescribing these medications concomitantly with SYMBYAX. Abnormal Bleeding — Published case reports have documented the occurrence of bleeding episodes in patients treated with psychotropic drugs that interfere with serotonin reuptake. Subsequent epidemiological studies, both of the case-control and cohort design, have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake. Subsequent patrointestinal bleeding, in two studies, concurrent use of a nonstroid anti-inflammatory drug (NSAID) or aspirin potentiated the risk of bleeding (see DRUG INTEFACTIONS). Although these studies focused on upper gastrointestinal bleeding, there is reason to believe that bleeding at other sites may be similarly potentiated. Patients should be cautioned regarding the risk of bleeding associated with the concomitant use of SYMBYAX with NSAIDs, aspirin, or other drugs that affect cacquilation. Mania/Hypomania — In the two controlled bipolar depression studies there was no statistically significant difference in the incidence of manic events (manic reaction or manic depressive reaction) between SYMBYAX- and placebo-treated patients. In one of the studies, the incidence of manic events was (7% [3/43]) in SYMBYAX-treated patients compared to (3% [5/184]) in placebo-treated patients. In the other retartment of bipolar depression makes it difficult to interpret these findings until additional data is obtained. Because of this and the cyclical nature of bipolar disorder, patients should be monitored closely for the development of symptoms of manic Appropriate care is advised when prescribing SYMBYAX. Body Temperature Regulation — Disruption of the body's ability to reduce core body temperature has we will be experiencing conditions which may contribute to an elevation in ore robust prepared (e.g., exercising strenuously, exposure to extreme heat, receiving conomitant medication with anticholinergic activity, or bein

ivity, or being subject to dehydration). olinergic act

Cognitive and Motor Impairment — Somnolence was a commonly reported adverse event associated with SYMBYAX treatment, occurring at an incidence of 22% in SYMBYAX patients compared with 11% in placebo patients. Somnolence led to discontinuation in 2% (10/571) of patients in the premarketing controlled clinical studies.

controlled clinical studies. As with any CNS-active drug, SYMBYAX has the potential to impair judgment, thinking, or motor Patients should be cautioned about operating hazardous machinery, including automobiles, until the reasonably certain that SYMBYAX therapy does not affect them adversely.

reasonably certain that SYMBYAX therapy does not affect them adversely. **Discontinuation of Treatment with SYMBYAX** During marketing of fluoxetine, a component of SYMBYAX, and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, contision, headache, lethargy, emotional lability, insomia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with fluoxetine. A gradual reduction in the dose rather than abrupt cessation is ecommended whenever possible. If intolerable symptoms occur interaction of the case of the considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Plasma fluxetine and norfluxetine concentration decreasing the the conclusion of therapy, which may minimize the risk of discontinuation symptoms with this drug (see DOSAGE AND ADMINISTRATION).

symptoms should be reported to the patients prescriber of nearlin processional, especially in they are severe, abrupt in onset, or were not part of the patients prescribing symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication. Abnormal Bleeding — Patients should be cautioned about the concomitant use of SYMBYAX and NSAIDs, aspirin, or other drugs that affect coagulation since the combined use of psychotropic drugs that interfere with serotonin requirake and these agents has been associated with an increased risk of bleeding (see PRECAUTIONS, Abnormal Bleeding).

Alcohol — Patients should be advised to avoid alcohol while taking SYMBYAY

Alcohol — Patients should be advised to avoid alconol while taking or IND TAA. Cognitive and Motor Impairment — As with any CNS-active drug, SYMBYAX has the potential to pair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous achinery, including automobiles, until they are reasonably certain that SYMBYAX therapy does not affect them adversely Concomitant Medication — Patients should be advised to inform their physician if they are taking

Prozac[®], Prozac Weekly™, Sarafem[®], fluoxetine, Zyprexa[®], or Zyprexa Zydis[®], Patients should also be advised to inform their physicians if they are taking or plan to take any prescription or over-the-counter drugs, including herbal supplements, since there is a potential for interactions. Heat Exposure and Dehydration - Patients should be advised regarding appropriate care in avoiding

Nursing — Patients, if taking SYMBYAX, should be advised not to breast-feed.

Orthostatic Hypotension — Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration and in association with the use of concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam or alcohol (see WARNINGS and Due laterative)

Treatment Adherence — Patients should be advised to take SYMBYAX exactly as prescribed, and to ontinue taking SYMBYAX as prescribed even after their mood symptoms improve. Patients should be dvised that they should not alter their dosing regimen, or stop taking SYMBYAX, without consulting part physicians.

Patient information is printed at the end of this insert. Physicians should discuss this information with their patients and instruct them to read the Medication Guide before starting therapy with SYMBYAX and each time their prescription is refilled.

Laboratory Tests ssessment of transaminases is recommended in patients with significant hepatic disease

(see Transaminase Elevations)

Drug Interactions The risks of using SYMBYAX in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions of the individual components are applicable to SYMBYAX. As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic). pharmacokinetic drug inhibition or enhancement, etc.) is a possibility. Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required. In evaluating individual cases, consideration should be given to using lower initial doaes of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status (see CLINICAL PHARMACOLOGY, Accumulation and slow elimilation).

Antihypertensive agents — Because of the potential for olanzapine to induce hypotension, SYMBYAX may enhance the effects of certain antihypertensive agents (see WARNINGS, Orthostatic Hypotension). Anti-Parkinsonian — The olanzapine component of SYMBYAX may antagonize the effects of leve and dopamine agonists.

Benzodiazepines — Multiple doses of olanzapine did not influence the pharmacokinetics of diazepam and its active metabolite N-desmethyldiazepam. However, the coadministration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine.

When concurrently administered with fluxetine, the half-life of diazepam may be prolonged in some patients (see CLINICAL PHARMACOLOGY, Accumulation and slow elimination). Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.

Biperiden — Multiple doses of olanzapine did not influence the pharmacokinetics of biperiden

 $\underline{Carbamazepine} - Carbamazepine therapy (200 mg BID) causes an approximate 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP142 activity. Higher daily doess of carbamazepine may cause an even greater increase in$

Inzapine clearance. Patients on stable doses of carbamazepine have developed elevated plasma anticonvulsant ncentrations and clinical anticonvulsant toxicity following initiation of concomitant flucxetine treatment. <u>Clozapine</u> — Elevation of blood levels of clozapine has been observed in patients receiving recomitant flucxetion Clozapine -

Electroconvulsive therapy (ECT) — There are no clinical studies establishing the benefit se of ECT and fluoxetine. There have been rare reports of prolonged seizures in patier

use of ECT and fluxwatine. There have been rare reports of prolonged seizures in patients on fluxwetine receiving ECT treatment (see Seizures). Ethanol — Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine pharmacokinetics. The coadministration of ethanol with SYMBYAX may potentiate sedation and orthostatic hypotension. <u>Eluxwarmine</u> — Fluxvasmine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine C_{max} following fluxvasmine administration of 54% in female nonsweters and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of the olanzapine component of SYMBYAX should be considered in patients receiving concomitant treatment with fluxvasmine. treatment with fluvoxamine

Haloperidol - Elevation of blood levels of haloperidol has been observed in patients receiving omitant fluoxetine

Lithium — Multiple doses of olanzapine did not influence the pharmacokinetics of lithium.

There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic efficts have been reported. Lithium levels should be monitored in patients taking SYMBYAX concomitantly with lithium.

Monoamine oxidase inhibitors — See CONTRAINDICATIONS. - Patients on stable doses of phenytoin have developed elevated plasma levels of phenytoin Phenytoin with clinical phenytoin toxicity following initiation of concomitant fluoxetine

<u>Pimozide</u> — Clinical studies of pimozide with other antidepressants demonstrate an increase in drug teraction or QT_c prolongation. While a specific study with pimozide and fluoxetine has not been conducted, the potential for d pimozide and fluoxetine. (see CONTRAINDICATIONS) ntial for drug interactions or QT_c prolongation warrants restricting the concurrent use of oxetine. Concomitant use of fluoxetine and pimozide is contraindicated

Sumatriptan — There have been rare postmarketing reports describing patients with weakness, perreflexia, and incoordination following the use of an SSRI and sumatriptan. If concomitant treatment th sumatriptan and an SSRI (e.g., fluoxetine, fluoxamine, paroxetine, sertraline, or citalopram) is clinically arranted, appropriate observation of the patient is advised.

Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or metabolites. its Thioridazine — See CONTRAINDICATIONS and WARNINGS. Thioridazine

<u>Thicridazing</u> — See CONTRAINDICATIONS and WARNINGS, Thioridazine. <u>Tricyclic antidepressants (TCAs)</u> — Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine. In two fluoxetine studies, previously stable plasma levels of imipramine and desipramine have increased >2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for three weeks or longer after fluoxetine is discontinued. Thus, the dose of TCA may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when SYMBYAX is coadministered or has been recently discontinued (see Drugs metabolized by CYP2D6 and CLINICAL PHARMACOLOGY, Accumulation and slow elimination).

Trytophan — Five patients receiving fluoxetine in combination with tryptophan experienced adverse actions, including agitation, restlessness, and gastrointestinal distress.

<u>Valproate</u> — In vitro studies using human liver microsomes determined that olanzapine has little potential inhibit the major metabolic pathway, glucoronidation, of valproate. Further, valproate has little effect on e metabolism of olanzapine in vitro. Thus, a clinically significant pharmacokinetic interaction between anzapine and valproate is unlikely. <u>Warfarin</u> — Warfarin — Warfarin — Warfarin (20-mg single dose) did not affect loanzapine pharmacokinetics. Single doses of anzapine did not affect the pharmacokinetics of warfarin.

<u>wantam</u> — wantam (20-mg single dose) did not affect blanzapine priamtacokinetics. Single doses of anzapine did not affect the pharmacokinetics of warfarin. Altered anticoagulant effects, including increased bleeding, have been reported when fluoxetine is padministered with warfarin (see PRECAUTIONS, Abnormal Bleeding). Patients receiving warfarin therapy nould receive careful coagulation monitoring when SYMBYAX is initiated or stopped.

Drugs that interfere with hemostasis (NSAIDs, aspirin, warfarin, etc.) — Serotonin release by platelets avs an important role in hemostasis. Epidemiological studies of the case-control and cohort design that

have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding (see PRECAUTIONS, Abnormal Bleeding). Thus, patients should be cautioned about the use of such drugs concurrently with SYMBYAX. <u>Drugs metabolized by CYP2D6</u> — In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP2D6. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by this enzyme. Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as poor metabolizers of drugs such as dother selective uptake inhibitors of serotonin, are metabolized by this isoenzyme; thus, bott the pharmacokinetic properties and relative proportion of metabolites are altered in poor metabolizers. However, for fluxestine

selective uptake inhibitors of serotonin, are metabolized by this isoenzyme; thus, both the pharmacokinetic properties and relative proportion of metabolites are altered in poor metabolizers. However, for fluxetine and its metabolite, the sum of the plasma concentrations of the 4 enantiomers is comparable between poor and extensive metabolizers (see CLINICAL PHARMACOLOGY, Variability in metabolism). Fluxetine, like other agents that are metabolized by CYP2D6, inhibits the activity of this isoenzyme, and thus may make normal metabolizers resemble poor metabolizers. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluxetine concurrently or has sken it in the previous five weeks. If fluxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for a decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (including but not limited to, flecainide, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated thioridazine plasma levels, thioridazine should not be deministered with fluxekine or within a minimum of five weeks. Horidazine has been discontinued (see CONTRAINDICATIONS, Monoamine Oxidase Inhibitors (MAOI) and WARNINGS, Thioridazine). Drugs metabolized by CYP3D

<u>Drugs metabolized by CYP3A</u> — In vitro studies utilizing human liver microsomes suggest that anzapine has little potential to inhibit CYP3A. Thus, olanzapine is unlikely to cause clinically important

In an in vivo interaction study involving the coadministration of fluoxetine with single doses of terfenadine

(a CYP3A substrate), no increase in plasma tertenadine concentrations occurred with concomitan fluoxetine. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of severa substrates for this enzyme, including astemizole, cisapride, and midazofam. These data indicate tha fluoxetine's extent of inhibition of CYP3A activity is not likely to be of clinical significance.

Effect of olanzapine on drugs metabolized by other CYP enzymes — In vitro studies utilizing human liver icrosomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, and CYP2C19. Thus,

olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes

drug interactions mediated by these enzymes.

have demonstrated an association between use of psychotropic drugs that interfere with serotonin r

Study 2	SYMBYAX (N=42)	32	-18 ^a
	Olanzapine (N=169)	33	-14
	Placebo (N=174)	31	-9

Negative number denotes imp ent from baseline.

Placebo (N=181)

Study

e and placebo cally signific



Dysphagia — Esophageal dysmotility and aspiration have been associated with antipsychotic drug use spiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's sease. Olanzapine and other antipsychotic drugs should be used cautiously in patients at risk for entities exercised.

aspiration pneurionia. **Half-Life** — Because of the long elimination half-lives of fluoxetine and its major active metabolite, changes in dose will not be fully reflected in plasma for several weeks, affecting both strategies for tirration to final dose and withdrawal from treatment (see CLINICAL PHARMACOLOGY, Accumulation and slow elimination)

Hyperprolactinemia — As with other drugs that antagonize dopamine D₂ receptors, SYMBYAX elevates rolactin levels, and a modest elevation persists during administration; however, possibly associated clinical anifestations (e.g., galactorrhea and breast enlargement) were infrequently observed.

The effect of other drugs on olanzapine — Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Agents that induce Delatance a small almount (see CLINICAL PRAMMACUCON, Pharmacontineucs). Ageins intal induce CYP1A2 or glucuronyl transferase enzymes, such as comeprazole and rifampin, may cause an increase in olanzapine clearance. Fluvoxamine, an inhibitor of CYP1A2, decreases olanzapine clearance (see Drug Interactions, Fluvoxamine). The effect of CYP1A2 inhibitors, such as fluvoxamine and some fluvorquinolone antibiotics, on SYMBYAX has not been evaluated. Although olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a single enzyme may appreciably alter olanzapine clearance. Therefore, a dosage increase (for induction) or a dosage decrease (for inhibition) may need to be considered with specific drune. specific drugs.

specific drugs. <u>Drugs tightly bound to plasma proteins</u> — The in vitro binding of SYMBYAX to human plasma proteins is similar to the individual components. The interaction between SYMBYAX and other highly protein-bound drugs has not been fully evaluated. Because fluoxetine is tightly bound to plasma protein, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely, adverse effects may result from displacement of protein-bound fluoxetine by other tightly bound drugs (see CLINICAL PHARMACOLOGY, Distribution and PRECAUTIONS, Drug Interactions).

SYMBYAX® (olanzapine and fluoxetine HCl capsules)

Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity, mutagenicity, or fertility studies were conducted with SYMBYAX. The following data are based on findings in studies performed with the individual components.

are based on findings in studies performed with the individual components. Carcinogenesis <u>Dianzapine</u> — Oral carcinogenicity studies were conducted in mice and rats. Olanzapine was administered to mice in two 78-week studies at doses of 3, 10, and 30/20 mg/kg/day [equivalent to 0.8 to 5 times the maximum recommended human daily dose (MRHD) on a mg/m² basis] and 0.25, 2, and 8 mg/kg/day (equivalent to 0.06 to 2 times the MRHD on a mg/m² basis). Rats were dosed for 2 years at doses of 0.25, 1, 2.5, and 4 mg/kg/day (males) and 0.25, 1, 4, and 8 mg/kg/day (equivalent to 0.16 to 1 to 2 and 0.1 to 4 times the MRHD on a mg/m² basis, respectively). The incidence of liver hemangiomas and hemangioarcomas was significantly increased in one mouse study in females dosed at 8 mg/kg/day (2 times the MRHD on a mg/m² basis). These tumors were not increased in another mouse study in females dosed at 10 or 30/20 mg/kg/day (2 to 5 times the MRHD on a mg/m² basis); in this study, there was a high incidence of early mortalities in males of the 30/20 mg/kg/day group. The incidence of marmary gland adenomas and adenocarcinomas was significantly increased in female mice dosed at ≥ 2 mg/kg/day and in female rats dosed at ≥4 mg/kg/day (0.5 and 2 times the MRHD on a mg/m² basis. Serum prolactin levels were not measured during the clanzapine carcinogenicity studies; however, measurements during subchronic toxicity studies showed that olanzapine elevated serum prolactin levels up to 4-loid in rats at the same doses used in the carcinogenicity studie; however, measurements during subchronic tarker theronic administration of other antipsychotic drugs and is considered to be and in rodents after chronic administration of other antipsychotic drugs and is considered to be the findemet of the chronic administration of other antipsychotic drugs and is considered to be same bases used in the carcinogenicity such An increase in maintary gland neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be protactin-mediated. The relevance for human risk of the finding of protactin-mediated endocrine tumors in rodents is unknown (see PEECAUTIONS, Hyperprotactinemia). <u>Elucostina</u> — The dietary administration of fluoxetine to rats and mice for two years at doses of up to 10 and 12 mg/kg/day, respectively (approximately 1.2 and 0.7 times, respectively, the MRHD on a mg/m² basis), produced no evidence of carcinogenicity.

Mutagenesis

Mutagenesis <u>Clanzagine</u> — No evidence of mutagenic potential for olanzapine was found in the Ames reverse mutation test, in vivo micronucleus test in mice, the chromosomal aberration test in Chinese hamster ovary cells, unscheduled DNA synthesis test in rat hepatocytes, induction of forward mutation test in mouse lymphoma cells, or in vivo sister chromatid exchange test in hone marrow of Chinese hamsters. <u>Elucostine</u> — Flucetine and norflucetine have been shown to have no genotoxic effects based on the following assays: bacterial mutation assay. DNA repair assay in cultured rat hepatocytes, mouse lymphoma assay, and in vivo sister chromatid exchange eassay in Chinese hamster bone marrow cells.

Impairment of Fertility SYMBYAX — Fertility studies were not conducted with SYMBYAX. However, in a repeat-dose

SYMBYAX — Fertilia Sology study of three $\underline{SYMBYAX}$ — Fertility studies were not conducted with SYMBYAX. However, in a repeat-dose rat toxicology study of three months duration, ovary weight was decreased in females treated with the low-dose [2 and 4 mg/kg/day (1 and 0.5 times the MRHD on a mg/m² basis), respectively] and high-dose [4 and 8 mg/kg/day (2 and 1 times the MRHD on a mg/m² basis), respectively] combinations of olanzapine and fluxatine. Decreased ovary weight, and corpora luteal depletion and uterine atrophy were observed to a greater extent in the females receiving the high-dose combination of an term ereceiving either olanzapine or fluxoteline alone. In a 3-month repeat-dose dog toxicology study, reduced epididymal sperm and reduced testicular and prostate weights were observed with the high-dose combination of olanzapine and fluxoteine [5 and 5 mg/kg/day (9 and 2 times the MRHD on a mg/m² basis), respectively] and with olanzapine lane (6 mg/kg/day q) on a mg /m² basis).

Olanzapine done (5 mg/kg/day or 9 times the MRHD on a mg/m² basis).
<u>Olanzapine</u> — In a fertility and reproductive performance study in rats, male mating performance, but not

<u>Olanzapine</u> — In a tertility and reproductive performance study in rats, male mating performance, but not fertility, was descreased at a dose of 2 mg/kg/day (11 and 1.5 times the MRHD on a mg/m² basis, respectively). Discontinuance of olanzapine treatment reversed the effects on male-mating performance. In female rats, the precoidal period was increased and the mating index reduced at 5 mg/kg/day (2.5 times the MRHD on a mg/m² basis). Diestrous was prolonged and estrous was delayed at 1.1 mg/kg/day (0.6 times the MRHD on a mg/m² basis); therefore, olanzapine may produce a delay in ovulation.

Eluoxetine — Two fertility studies conducted in adult rats at doses of up to 7.5 and 12.5 mg/kg/day pproximately 0.9 and 1.5 times the MRHD on a mg/m² basis) indicated that fluoxetine had no adverse effects on fertility (see Pediatric Use)

Pregnancy — Pregnancy Category C

SYMBYAN

Embryo fetal development studies were conducted in rats and rabbits with olanzapine and fluoxetine in Embryo fetal development studies were conducted in rats and rabbits with olanzapine and fluxetine in low-dose and high-dose combinations. In rats, the doses were: 2 and 4 mg/kg/day (low-dose) [1 and 0.5 times the MBHD on a mg/m² basis, respectively], and 4 and 8 mg/kg/day (high-dose) [2 and 1 times the MBHD on a mg/m² basis, respectively]. In rabbits, the doses were 4 and 4 mg/kg/day (low-dose) [4 and 1 times the MBHD on a mg/m² basis, respectively], and 8 and 8 mg/kg/day (high-dose) [9 and 2 times the MBHD on a mg/m² basis, respectively], and 8 and 8 mg/kg/day (high-dose) [9 and 2 times the MBHD on a mg/m² basis, respectively]. In these studies, olanzapine and fluxetine were also administered alone at the high-doses (4 and 8 mg/kg/day, respectively), in the rab fill and a mg/kg/day, respectively], in the rabit. In the rabit, there was no evidence of teratogenicity; however, the high-dose combination produced decreases in fetal weight and retarded skeletal osification in conjunction with maternal toxicity. Similarly, in the rab there was no evidence of teratogenicity; however, a decrease in fetal weight was observed with the high-dose combination.

high-dose combination. In a pre- and postnatal study conducted in rats, olanzapine and fluoxetine were administered during pregnancy and throughout lactation in combination (low-dose: 2 and 4 mg/kg/day [1 and 0.5 times the MHHD on a mg/m² basis], respectively, high-dose: 4 and 8 mg/kg/day [2 and 1 times the MHHD on a mg/m² basis], respectively, high-dose: 4 and 8 mg/kg/day [2 and 1 times the MHHD on a mg/m² basis], respectively, and alone: 4 and 8 mg/kg/day [2 and 1 times the MHHD on a mg/m² basis], respectively, and alone: 4 and 8 mg/kg/day [2 and 1 times the MHHD on a mg/m² basis], respectively, and alone: 4 and 8 mg/kg/day [2 and 1 times the MHHD on a mg/m² basis], respectively. Administration of the high-dose combination resulted in a marked elevation in offspring mortality and growth retardation in comparison to the same doses of olanzapine and fluoxetine administered alone. These effects were not observed with the low-dose combination; however, there were a few cases of testicular degeneration and atrophy, depletion of epididymal sperm and infertility in the male progeny. The effects of the high-dose combination results could not be assessed due to high progeny mortality.

rogeny mortany. are are no adequate and well-controlled studies with SYMBYAX in pregnant womer THERE are TO ADEQUATE AND WEIl-controlled studies with SYMBYAX in pregnant women. SYMBYAX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Usanzapine In reproduction studies in rats at doses up to 18 mg/kg/day and in rabbits at doses up to 30 mg/kg/day (9 and 30 times the MRHD on a mg/m² basis, respectively), no evidence of teratogenicity was observed in a rat teratology study, early resorptions and increased numbers of norviable fetuses were observed at a dose of 18 mg/kg/day (9 times the MRHD on a mg/m² basis). Gestation was prolonged at 10 mg/kg/day (5 times the MRHD on a mg/m² basis). In a rabbit teratology study, fetal toxicity (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic dose of 30 mg/kg/day (30 times the MRHD on a mg/m² basis). Placental transfer of olanzapine occurs in at pure

Placental transfer of olanzapine occurs in rat pups

There are no adequate and well-controlled clinical studies with olanzapine in pregnant women. Seven pregnancies were observed during premarketing clinical studies with olanzapine, including two resulting in normal births, one resulting in neonatal death due to a cardiovascular defect, three therapeutic abortions, and one spontaneous abortion.

Fluoxetine In embryo fetal development studies in rats and rabbits, there was no evidence of teratogenicity following administration of up to 12.5 and 15 mg/kg/day, respectively (1.5 and 3.6 times the MRHD on a mg/m² basis, respectively) throughout organogenesis. However, in rat reproduction studies, an increase in stilborn pups, a decrease in pup weight, and an increase in pup deaths during the first 7 days postpartum occurred following maternal exposure to 12 mg/kg/day (1.5 times the MRHD on a mg/m² basis) during gestation or 7.5 mg/kg/day (0.9 times the MRHD on a mg/m² basis) during gestation and lactation. There was no evidence of developmental neurotoxicity in the surviving offspring of rats treated with 12 mg/kg/day during gestation. The no-effect dose for rat pup mortality was 5 mg/kg/day (0.6 times the MRHD on a mg/m² basis).

mgm[∠] basis). Nonteratogenic Effects — Neonates exposed to fluoxetine and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hypereflexia, tremor, jitteriness, irritability, ad constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see CONTRAINDICATIONS. Monoparing Outdoon Linter) t, in some cases, the clinical picture is consistent with serotonin syndrome (see CONTRAINDCATIONS, noamine Oxidase Inhibitors). When treating a pregnant woman with fluoxetine during the third trimester, physician should carefully consider the potential risks and benefits of treatment the physician should carefully co (see DOSAGE AND ADMINISTRATION).

SYMBYAX® (olanzapine and fluoxetine HCI capsules)

Body System/

Table 3: Treatment-Emergent Adverse Events: Incidence in Controlled Clinical Studies Percentage of Patients Reporting Event

Body System/ Adverse Event ¹	Percentage of Patients Reporting Event				
	SYM	Placebo			
	Bipolar Depression (N=86)	SYMBYAX-Controlled (N=571)	(N=477)		
Body as a Whole					
Asthenia	13	15	3		
Accidental injury	5	3	2		
Fever	4	3	1		
Cardiovascular System					
Hypertension	2	2	1		
Tachycardia	2	2	0		
Digestive System					
Diarrhea	19	8	7		
Dry mouth	16	11	6		
Increased appetite	13	16	4		
Tooth disorder	1	2	1		
Metabolic and Nutritional Disorders					
Weight gain	17	21	3		
Peripheral edema	4	8	1		
Edema	0	5	0		
Musculoskeletal System					
Joint disorder	1	2	1		
Twitching	6	2	1		
Arthralgia	5	3	1		
Nervous System					
Somnolence	21	22	11		
Tremor	9	8	3		
Thinking abnormal	6	6	3		
Libido decreased	4	2	1		
Hyperkinesia	2	1	1		
Personality disorder	2	1	1		
Sleep disorder	2	1	1		
Amnesia	1	3	0		
Respiratory System					
Pharyngitis	4	6	3		
Dyspnea	1	2	1		
Special Senses					
Amblyopia	5	4	2		
Ear pain	2	1	1		
Otitis media	2	0	0		
Speech disorder	0	2	0		
Urogenital System					
Abnormal ejaculation ²	7	2	1		
Impotence ²	4	2	1		
Anorgasmia	3	1	0		

Included are events reported by at least 2% of patients taking SYMBYAK except the following events, which had an incidence on placebo 2 SYMBYAK: abdomina plain, abnormal dreams, agitation, akathisia, anorexia, anxiety, apathy back pain, chest pain, constipation, cough increased, depression, dizziness, dysmenorrhea (adjusted for gender), dyspepsia, flatulence, flu syndrome, headacte, hypertonia, insormia, manic reaction, myalgia, nausea, nervousness, pain, palpitation, paresthesia, rash, rhinitis, sinusitis, sweating, vomiting. Adjusted for gende

nal Findings Observed in Clinical Studies The foll

Interolowing findings are based on clinical studies. <u>Effect on cardiac repolarization</u> — The mean increase in OT_c interval for SYMBYAX-treated patients (4.9 msec) in clinical studies was significantly greater than that for placebo-treated (-0.9 msec) and olanzapine-treated (0.6 msec) patients, but was not significantly different from fluxxetine-treated (0.7 msec) patients. There were no differences between patients treated with SYMBYAX, placebo, olanzapine, or fluxxetine in the incidence of OT_c outliers (>500 msec).

<u>Laboratory changes</u> — In SYMBYAX clinical studies, SYMBYAX was associated with asymptomatic mean increases in alkaline phosphatase, cholesterol, GGT, and uric acid compared with placebo (see PRECAUTIONS, Transaminase Elevations).

SYMBYAX was associated with a slight decrease in hemoglobin that was statistically significantly greater than that seen with placebo, olanzapine, and fluoxetine.

than that seen with placebo, olanzapine, and flucxetine. An elevation in serum prolactin was observed with SYMBYAX. This elevation was not statistically different than that seen with olanzapine (see PRECAUTIONS, Hyperprolactinemia). In olanzapine clinical studies among olanzapine-treated patients with random triglyceride levels of <150 mg/dL at baseline (N=659), 0.5% of patients experienced triglyceride levels of 2500 mg/dL anytime during the trials. In these same trials, olanzapine-treated patients (N=1185) had a mean increase of 20 mg/dL in triglycerides from a mean baseline value of 175 mg/dL.

In olanzapine placebo-controlled trials, olanzapine-treated patients with random cholesterol levels of <200 mg/dL at baseline (N=1034) experienced cholesterol levels of ≥240 mg/dL anytime during the trials

SYMBYAX® (olanzapine and fluoxetine HCl capsules)

indicated, dose escalation should be performed with caution in these patients. SYMBYAX has not been systematically studied in patients over 65 years of age or in patients <18 years of age (see WARNINGS, Orthostatic Hypotension, PRECAUTIONS, Pediatric Use, and Geriatric Use, and CLINICAL PHARMACOLOGY, Pharmacokinetics).

Treatment of Pregnant Women During the Third Trimester Neonates exposed to fluxetine, a component of SYMBYAX, and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with fluxetine during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering fluxetine at the third trimester.

Discontinuation of Treatment with SYMBYAX

EVISORUTINATION OF ITERTMENT WITH SYMBYAX Symptoms associated with discontinuation of fluoxetine, a component of SYMBYAX, and other SSRIs and SNRIs, have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If inclerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.

HOW SUPPLIED SYMBYAX capsules are supplied in 6/25-, 6/50-, 12/25-, and 12/50-mg (mg equivalent olanzapine/mg cetine^a) strength:

SYMBYAX	CAPSULE STRENGTH			
	6 mg/25 mg	6 mg/50 mg	12 mg/25 mg	12 mg/50 mg
Color	Mustard Yellow & Light Yellow	Mustard Yellow & Light Grey	Red & Light Yellow	Red & Light Grey
Capsule No.	PU3231	PU3233	PU3232	PU3234
Identification	Lilly 3231 6/25	Lilly 3233 6/50	Lilly 3232 12/25	Lilly 3234 12/50
NDC Codes	•			
Bottles 30	0002-3231-30	0002-3233-30	0002-3232-30	0002-3234-30
Bottles 100	0002-3231-02	0002-3233-02	0002-3232-02	0002-3234-02
Bottles 1000	0002-3231-04	0002-3233-04	0002-3232-04	0002-3234-04
Blisters IDb100	0002-3231-33	0002-3233-33	0002-3232-33	0002-3234-33

^a Fluoxetine base equivalent. ^b IDENTI-DOSE[®], Unit Dose Medication, Lilly.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature1

Keep tightly closed and protect from moisture

Keep tighty closed and protect from moisture. **ENIMAL TOXICOLOGY Fluoxetine** — In a juvenile toxicology study in CD rats, administration of 30 mg/kg of fluoxetine hydrochloride on postnatal days 21 through 90 resulted in increased serum activities of creatine hydrochloride on postnatal days 21 through 90 resulted in increased serum activities of creatine hydrochloride on postnatal days 21 through 90 resulted in increased serum activities of creatine hydrochloride on postnatal days 21 through 90 resulted in increased serum activities of creatine hydrochloride on postnatal days 21 through 90 resulted in increased serum activities of creatine degeneration, necrosis and regeneration. Other findings in rats administered 30 mg/kg included degeneration and necrosis of seminiferous tubules of the testis, epididymal epithelial vacuolation, and immaturity and inactivity of the female reproductive tract. Plasma levels achieved in these animals at 30 mg/kg were approximately 5-to 8-fold (fluoxetine) and 18- to 20-fold (norfluoxetine), and at 10 mg/kg approximately 2-fold (fluoxetine) and 8- told (norfluoxetine), higher compared to plasma concentrations usually achieved in pediatric patients. Following an approximate 11-week recovery period, sperm concentrations without affecting sperm morphology or motility. Microscopic evaluation of testes and epiddymides of these 30-mg/kg males indicated that testicular degeneration was irreversible. Delays in sexual maturation occurred in the 10-mg/kg males and in the 30-mg/kg increased to a lesser extent compared of these findings in humans is unknown. Femur lengths at 30 mg/kg increased to a lesser extent compared with control rats. with control rats

Medication Guide

About Using Antidepressants in Children and Teenagers

What is the most important information I should know if my child is being prescribed an antidepressant?

Parents or guardians need to think about 4 important things when their child is prescribed

1. There is a risk of suicidal thoughts or actions

- 2. How to try to prevent suicidal thoughts or actions in your child
- 3. You should watch for certain signs if your child is taking an antidepressant
- 4. There are benefits and risks when using antidepressants

1. There is a Risk of Suicidal Thoughts or Actions

Children and teenagers sometimes think about suicide, and many report trying to kill themselves. Antidepressants increase suicidal thoughts and actions in some children and teenagers. But suicidal thoughts and actions can also be caused by depression, a serious medical condition that is commonly treated with antidepressants. Thinking about killing yourself or trying to kill yourself is called suicidality or being suicidal.

A large study combined the results of 24 different studies of children and teenagers with depression or other illnesses. In these studies, patients took either a placebo (sugar pill) or an antidepressant for 1 to 4 months. **No one committed suicide in these studies**, but some patients became suicidal. On sugar pills, 2 out of every 100 became suicidal. On the antidepressants, 4 out of every 100 patients became suicidal.

For some children and teenagers, the risks of suicidal actions may be especially high. These include patients with

- · Bipolar illness (sometimes called manic-depressive illness)
- · A family history of bipolar illness
- A personal or family history of attempting suicide

If any of these are present, make sure you tell your health care provider before your child takes an antidepressant

2. How to Try to Prevent Suicidal Thoughts and Actions

To try to prevent suicidal thoughts and actions in your child, pay close attention to changes in her or his moods or actions, especially if the changes occur suddenly. Other important people in your child's life can help by paying attention as well (e.g., your child, brothers and sisters, teachers, and other important people). The changes to look out for are listed in Section 3, on what to watch for.

Whenever an antidepressant is started or its dose is changed, pay close attention to your child. After starting an antidepressant, your child should generally see his or her health care provider

· Once a week for the first 4 weeks

Labor and Delivery

SYMBYAX The effect of SYMBYAX on labor and delivery in humans is unknown. Parturition in rats was not affected by SYMBYAX. SYMBYAX should be used during labor and delivery only if the potential benefit

Olanzapine Parturition in rats was not affected by olanzapine. The effect of olanzapine on labor and delivery in

humans is unk

Fluoxetine The effect of fluoxetine on labor and delivery in humans is unknown. Fluoxetine crosses the placenta; therefore, there is a possibility that fluoxetine may have adverse effects on the newborn.

Nursing Mothers

SYMBYAX

There are no adequate and well-controlled studies with SYMBYAX in nursing mothers or infants. No studies have been conducted to examine the excretion of olarzapine or fluoveline in breast milk following SYMBYAX treatment. It is recommended that women not breast-feed when receiving SYMBYAX.

Olanzapine Olanzapine was excreted in milk of treated rats during lactation

Fluoxetine Fluoxetine is excreted in human breast milk. In one breast milk sample, the concentration of fluoxetine Fluoxetine is excreted in human breast milk. In one breast milk sample, the concentration of fluoxetine Fucketine is excreted in numan breast mixe, an one breast mixe samples, the concentration on nucketine plus northuxetine was 70.4 ng/mL. The concentration in the mother's plasma was 295.0 ng/mL. No adverse effects on the infant were reported. In another case, an infant nursed by a mother on fluxetine developed crying, sleep disturbance, vomiting, and watery stools. The infant's plasma drug levels were 340 ng/mL of fluxetine and 208 ng/mL of northuxetine on the 2nd day of feeding.

Pediatric Use

Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS, Clinical Worsening and Suicide Risk). Anyone considering the use of SYMBYAX in a child or adolescent must balance the potential risks with the clinical need.

Fluozetine Significant toxicity, including myotoxicity, long-term neurobehavioral and reproductive toxicity, and impaired bone development, has been observed following exposure of juvenile animals to fluoxetine. Some of these effects occurred at clinically relevant exposures. In a study in which fluoxetine (3, 10, or 30 mg/kg) was orally administered to young rats from weaning (Postnatal Day 21) through adulthood (Day 90), male and female sexual development was delayed at all doses, and growth (body weight gain, femur length) was decreased during the dosing period in animals receiving the highest dose. At the end of the treatment period, serum levels of creatine kinase (marker of muscle damage) were increased at the intermediate and high doses, and abnormal muscle and evenoductive organ biotenotobory (seletated muscle denengration and hecrosic testicular denengration and Inuscie daniage) were increased at the interintediate and high doses, and adhorman muscle and reproductive organ histopathology (skellatal muscle adopenration and necrosis, testicular degeneration and necrosis, epididymal vacuolation and hypospermia) was observed at the high dose. When animals were evaluated after a recovery period (up to 11 weeks after cessation of dosing), neurobehavioral abnormalities (decreased reactivity at all doses and learning deficit at the high dose) and reproductive functional impairment (decreased mating at all doses and impaired fertility at the high dose) were seen; in addition, testicular and epididymal microscopic lesions and decreased sperm concentrations were found in the high reliable. Usincular and epulymain increaseble relations and decreased sperm concentrations were following in the negro-dose group, indicating that the reproductive organ effects seen at the end of treatment were irreversible. The reversibility of fluoxetine-induced muscle damage was not assessed. Adverse effects similar to those observed in rats treated with fluoxetine during the juvenile period have not been reported after administration of fluoxetine to adult animals. Plasma exposures (AUC) to fluoxetine in juvenile rats receiving the low, intermediate, and high dose in this study were approximately 0.1-0.2, 1-2, and 5-10 times, respectively, the average exposure in pediating patients receiving the maximum recommended dose (MRD) of approximative patients receiving the maximum recommended dose (MRD). of 20 mg/day. Rat exposures to the major metabolite, norfluoxetine, were approximately 0.3-0.8, 1-8, and 3-20 times, respectively, pediatric exposure at the MRD.

A specific effect of fluoxetine on bone development has been reported in mice treated with fluoxetine during the juvenile period. When mice were treated with fluoxetine (5 or 20 mg/kg, intraperionae)) for 4 weeks starting at 4 weeks of age, bone formation was reduced resulting in decreased bone mineral content and density. These doses did not affect overall growth (body weight gain or femoral length). The doses administered to juvenile mice in this study are approximately 0.5 and 2 times the MRD for pediatric patients on a body surface area (mg/m²) basis.

In another mouse study, administration of fluoxetine (10 mg/kg intraperitoneal) during early postnatal development (Postnatal Days 4 to 21) produced abnormal emotional behaviors (decreased exploratory behavior in elevated plus-maze, increased shock avoidance latency) in adulthood (12 weeks of age). The dose used in this study is approximately equal to the pediatric MRD on a mg/m² basis. Because of the early dosing period in this study, the significance of these findings to the approved pediatric use in humans is uncertain.

(See ANIMAL TOXICOLOGY.)

Geriatric Use SYMBYAX

SYMBYAX Clinical studies of SYMBYAX did not include sufficient numbers of patients ≥65 years of age to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, does selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see DOSAGE AND ADMINISTRATION)

Therapy (see DOSAGE AND Administration, Olanzapine Of the 2500 patients in premarketing clinical studies with olanzapine, 11% (263 patients) were ≥65 years of age. In patients with schizophrenia, there was no indication of any different tolerability of olanzapine in the elderly compared with younger patients. Studies in patients with demantia-related psychosis have suggested that there may be a different tolerability profile in this population compared with younger patients with schizophrenia. In placebo-controlled studies of olanzapine in elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis. If the prescriber elects to treat elderly patients with dementia-related psychosis, vigilance should be exercised (see BOX WARNING, WARNINGS, PRECAUTIONS, Use in Patients with Concomitant Illness and DOSAGE AND ADMINISTRATION, Special Populations)

As with other CNS-active drugs, olanzapine should be used with caution in elderly patients with dementia. Also, the presence of factors that might decrease pharmacokinetic clearance or increase the pharmacodynamic response to olanzapine should lead to consideration of a lower starting dose for any geriatric patient.

Fluoxetine Flucxetine US flucxetine clinical studies (10,782 patients) included 687 patients ≥65 years of age and 93 patients ≥75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. As with other SSRIs, flucxetine has been associated with cases of clinically significant the other sensitivity in block to the sensitivity of some older of the sensitivity of the sensitity of the sensitivity of the sensi nia in elderly patients.

ADVERSE REACTIONS

ADVERSE REACTIONS The information below is derived from a premarketing clinical study database for SYMBYAX consisting of 2066 patients with various diagnoses with approximately 1061 patient-years of exposure. The conditions and duration of treatment with SYMBYAX varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or long-term exposure.

Adverse events were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a limited (i.e., reduced) number of standardized event categories.

number or standardized event dategories. In the tables and tabulations that follow, COSTART Dictionary terminology has been used to classify reported adverse events. The data in the tables represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is possible that events reported during therapy were not necessarily related to drug exposure. The presenting a council the forward is the forward in the the forward in the tables and tabulation event the used.

The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevaled in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing clinician with some basis for estimating the relative contribution of drug and non-drug factors to the side effect incidence rate in the population studied.

Incidence in Controlled Clinical Studies

The following findings are based on the short-term, controlled premarketing studies in various diagnoses including bipolar depression.

Adverse events associated with discontinuation of treatment — Overall, 10% of the patients in the SYMBYAX group discontinued due to adverse events compared with 4.6% for placebo. Table 2 enumerates the adverse events leading to discontinuation associated with the use of SYMBYAX (incidence of at least 1% for SYMBYAX and greater than that for placebo). The bipolar depression column shows the incidence of adverse events with SYMBYAX in the bipolar depression studies and the "SYMBYAX-Controlled" column shows the incidence in the controlled SYMBYAX studies; the placebo column shows the incidence in the pooled controlled studies that included a placebo arm

Table 2: Adverse Events Associated with Discontinuation*

Adverse Event	Percentage of Patients Reporting Event				
	SYM	Placebo			
	Bipolar Depression (N=86)	SYMBYAX-Controlled (N=571)	(N=477)		
Asthenia	0	1	0		
Somnolence	0	2	0		
Weight gain	0	2	0		
Chest pain	1	0	0		
* Table includes events ass	ociated with discontinuation of	at least 1% and greater than p	lacebo		

Commonly observed adverse events in controlled clinical studies — The most commonly observed verse events associated with the use of SYMBYAX (incidence of >5% and at least twice that for placebo

in the SYMBYAX-controlled database) were: asthenia, edema, increased appetite, peripheral edema pharyngitis, somnolence, thinking abnormal, tremor, and weight gain. Adverse events occurring at an incidence of 2% or more in controlled clinical studies — Table 3 numerates the treatment-emergent adverse events associated with the use of SYMBYAX (incidence of at enu enumerates the treatment-emergent adverse events associleast 2% for SYMBYAX and twice or more that for placebo).

-200 mg/dL at baseline (M=1034) experienced cholesterol levels of 2240 mg/dL anytime during the trials once often than placebo-treated patients (N=602(3, 6% vs 2.2%, respectively). In these same trials, olanzapine-treated patients (N=62528) had a mean increase of 0.4 mg/dL in cholesterol from a mean baseline value of 203 mg/dL, which was significantly different compared to placebo-treated patients (N=145) with a mean decrease of 4.6 mg/dL from a mean baseline value of 203 mg/dL. Sexual dystunction — In the pool of controlled SYMBYAX studies, there were higher rates of the treatment-emergent adverse events decreased libid, anorgasmai, impotence and abnormal ejaculation in the SYMBYAX group than in the placebo group. One case of decreased libido led to discontrulation in the SYMBYAX group were less than the rates in the fluoxetine group. None of the differences were attainted viewing that one and experiment decreased in the axis in the fluoxetine group. None of the symbolic viewing that the symbolic viewing that the symbolic viewing that the rates in the fluoxetine group. None of the differences were attainted viewing that the symbolic viewing that the viewing that the symbolic viewing that the differences were statistically significant

Sexual dysfunction, including priapism, has been reported with all SSRIs. While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.

<u>Vital signs</u> — Tachycardia, bradycardia, and orthostatic hypotension have occurred in SYMBYAX-treated atients (see WARNINGS, Orthostatic Hypotension). The mean pulse of SYMBYAX-treated patients was duced by 1.6 beats/min.

Other Events Observed in Clinical Studies

Following is a list of all treatment-emergent adverse events reported at anytime by individuals taking SYMBYAX in clinical studies except (1) those listed in the body or footnotes of Tables 2 and 3 above o elsewhere in labeling, (2) those for which the COSTART terms were uninformative or misleading, (3) those events for which a causal relationship to SYMBYAX use was considered remote, and (4) events occurring in only 1 patient treated with SYMBYAX and which did not have a substantial probability of being acutely nreatening

Events are classified within body system categories using the following definitions: frequent adverse events are defined as those occurring on 1 or more occasions in at least 1/100 patients, infrequent adverse events are those occurring in 1/100 to 1/1000 patients, and rare events are those occurring in

Body as a Whole — Frequent: chills, infection, neck pain, neck rigidity, photosensitivity reaction

Body as a Whole — Frequent: chills, intection, neck pain, neck riging, photoematin, reaction, irequent: cellulitis, cyst, hernia, intentional injury, intentional overdose, malaise, moniliasis, overdose, elvic pain, suicide attempt; Rare: death, tolerance decreased. Cardiovascular System — Frequent: migraine, vasodilatation; Infrequent: arrhythmia, bradycardia, rebrai schemia, electrocardiogram abnormal, hypotension, QT-interval prolonged; Rare: angina pectoris, trial arrhythmia, atrial fibrillation, bundle branch block, congestive heart failure, myocardial infarct, trial arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, bundle branch block, congestive heart failure, myocardial infarct, triad arrhythmia, triad fibrillation, trans invested peripheral vascular disorder. T-wave inverted

Directive System — Frequent: increased salivation thirst: Infrequent: cholelithiasis colitis eructation bigestive dystatin — receives interessed samaalon, includent, innequent, innequent, activational interess, etization, esophagitis, gastribit, gastronteritis, gingivitis, hepatomegaly, masea and vomiting, peptic ulcer, periodontal abscess, stomatitis, tooth caries; Rare: aphthous stomatitis, tead incontinence, gastrointestinal hemorrhage, gum hemorrhage, intestinal obstruction, liver fatty deposit, pancreatitis.

Endocrine System — Infrequent: hypothyroidism. Hemic and Lymphatic System — Frequent: ecchymosis; Infrequent: anemia, leukocytosis, mphadenopathy; Rare: coagulation disorder, leukopenia, purpura, thrombocythemia.

Metabolic and Nutritional — Frequent: generalized edema, weight loss; *Infrequent*: alcohol intolerance hydration, glycosuria, hyperilgemia, hypoglycemia, hypokalemia, obesity; *Rare*: acidosis, bilirubinemia eatinine increased, gout, hyperkalemia, hypoglycemic reaction.

Musculoskeletal System — Infrequent: arthritis, bone disorder, generalized spasm, leg cramps ndinous contracture, tenosynovitis; Rare: arthrosis, bursitis, myasthenia, myopathy, osteoporosis

meumatoid arthritis. Nervous System — Infrequent: abnormal gait, ataxia, buccoglossal syndrome, cogymheel rigidity, coma, confusion, depersonalization, dysarthria, emotional lability, euphoria, extrapyramidal syndrome, hostility, hypesthesia, hypokinesia, incoordination, movement disorder, mycolonus, neuralgia, neurosis, vertigo; *Rare*: acute brain syndrome, aphasia, dystonia, libido increased, subarachnoid hemorrhage, withdrawal syndrome.

Respiratory System — Frequent: bronchitis, lung disorder; Infrequent: apnea, asthma, epistaxis, iccup, hyperventilation, laryngitis, pneumonia, voice alteration, yawn; Rare: emphysema, hemoptysis, laryngismus

Skin and Appendages — Infrequent: acne, alopecia, contact dermatitis, dry skin, eczema, pruritis psoriasis, skin discoloration, vesiculobullous rash; Rare: exfoliative dermatitis, maculopapular rash skin ulcer.

Special Senses — Frequent: abnormal vision, taste perversion, tinnitus; Infrequent: abnormality of on, conjunctivitis, deafness, diplopia, dry eyes, eye pain, miosis; Rare: eye hemorrhage

Urgenital System – Frequent: breast pain, menorrhagia¹, uninary frequency, urinary incontinence, rinary tract infection; *Infrequent:* amenorrhea¹, breast enlargement, breast neoplasm, oystiki, dysuria, male lactation¹, fibrocystic breast¹, hematuria, hypomenorrhea¹, leukorthea¹, menopause¹ netrorrhagi¹, oliguria, ovarian disorder¹, polyuria, urinary retention, urinary urgency, urination impaired aginal hemorrhage¹, vaginal moniliasi¹, vaginitis¹, Fare: breast carcinoma, breast engorgement, ndometrial disorder¹, gynecomastia¹, kidney calculus, uterine fibroids enlarged¹. urinary tract mess-female lactation¹, metrorrhagia¹, oligur vaginal hemo Adjusted for gender.

Observed with Olanzapine or Fluoxe

The following adverse events were not observed in SYMBYAX-treated patients during premarketing clinical studies but have been reported with olanzapine or fluoxetine monotherapy: aplastic anemia cholestatic jaundice, diabetic coma, dyskinesia, eosinophilic pneumonia, erythema multiorme, hepatitis, idiosyncratic hepatitis, priapism, pulmonary embolism, rhabdomyolysis, serotonin syndrome, serum sickness-like reaction, sudden unexpected death, suicidal ideation, vasculitis, venous thromboembolic events (including pulmonary embolism and deep venous thrombosis), violent behaviors. Random cholesterol levels of 2240 mg/dL and random triglycerdie levels of 21000 mg/dL have been rarely reported.

consesteroi levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been rarely reported.
 DRUG ABUSE AND DEPENDENCE
 Controlled Substance Class — SYMBYAX is not a controlled substance.
 Physical and Psychological Dependence — SYMBYAX is with fluxetine and olanzapine, has not
 been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. While
 the objective drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should
 carefully evaluate patients for history of drug abuse and follow such patients for olsely, observing them for
 signs of misuse or abuse of SYMBYAX (e.g., development of tolerance, incrementation of dose,
 drug-seeking behavior).
 In studies in rats and these members deviced

Ug-seeking benavor). In studies in rats and rhesus monkeys designed to assess abuse and dependence potential, olanzapine one was shown to have acute depressive CNS effects but little or no potential of abuse or physica spendence at oral doses up to 15 (rat) and 8 (monkey) times the MRHD (20 mg) on a mg/m² basis. OVERDOSAGE

remarketing clinical studies of the olanzapine/fluoxetine combination, overdose of both pine were reported in five study subjects. Four of the five subjects experience ess (3) or coma (1). No fatalities occurred.

consciousness (3) or coma (1). No fatalities occurred. Since the market introduction of olanzapine in October 1996, adverse event cases involving combination use of fluxetine and olanzapine have been reported to Eli Lilly and Company. An overdose of combination therapy is defined as confirmed or suspected ingestion of a dose of olanzapine 20 mg or greater in combination with a dose of fluxetine 80 mg or greater. As of 1 February 2002, 12 cases of combination therapy overdose were reported, most of which involved additional substances. Adverse events associated with these reports included somnolence; impaired consciousness (coma, lethargy); impaired neurologic function (ataxia, confusion, convulsions, dysarthria); arrhythmias; and fatality. Fatalities have been confounded by exposure to additional substances including alcohol, thioridazine, swenchen and enconvulsence. oxycodone, and propoxyphene.

Olarzapine In postmarketing reports of overdose with olanzapine alone, symptoms have been reported in the majority of cases. In symptomatic patients, symptoms with ≥10% incidence included agitation/aggressiveness, dysarthria, tachycardia, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. Among less commonly reported symptoms were the following potentially medically serious events: aspiration, cardiopulmonary arrest, cardiac arrhythmias (such as supraventricular tachycardia as well as a patient that experienced sinus pause with spontaneous resumption of normal rhythm), delirium, possible neuroleptic matignant syndrome, respiratory depression/arrest, convulsion, hypertension, and hypotension. Eli Lilly and Company has received reports of fatality in association with overdose of olanzapine alone. In 1 case of death, the amount of acutely ingested olanzapine was reported to be possibly as low as 450 mg; however, in another case, a patient was reported to survive an acute olanzapine ingestion of 1500 mg. **Fluoxetine**

Fluoxetine

Worldwide exposure to fluoxetine is estimated to be over 38 million patients (circa 1999). Of the 1578 cases of overdose involving fluoxetine, alone or with other drugs, reported from this population, there were 195 deaths.

were 195 deaths. Among 633 adult patients who overdosed on fluoxetine alone, 34 resulted in a fatal outcome, 378 completely recovered, and 15 patients experienced sequelae after overdose, including abnormal accommodation, abnormal gait, confusion, unresponsiveness, nervousness, pulmonary dysfunction, vertigo, remor, elevated blood pressure, impotence, movement disorder, and hypomania. The remaining 206 patients had an unknown outcome. The most common signs and symptoms associated with non-fatal

206 patients had an unknown outcome. The most common signs and symptoms associated with non-fatal overdose were seizures, somnolence, nausea, tachycardia, and vomiting. The largest known ingestion of fluoxetine in adult patients was 8 grams in a patient who took fluoxetine alone and who subsequently recovered. However, in an adult patient who took fluoxetine alone, an ingestion as low as 520 mg has been associated with lethal outcome, but causality has not been established. Among pediatric patients (ages 3 months to 17 years), there were 156 cases of overdose involving fluoxetine alone or in combination with other drugs. Six patients died, 127 patients completely recovered, 1 patient experienced renal failure, and 22 patients had an unknown outcome. One of the 6 fatalities was a 9-year-old boy who had a history of OCD, Tourette's Syndrome with tics, attention deficit disorder, and fetal alcohol syndrome. He had been receiving 100 mg of fluoxetine daily for 6 months in addition to cionidine, entrylyhenidate, and promethazine. Nixed-drug ingestion or other methods of suicide complicated all 6 overdoses in children that resulted in fatalities. The largest ingestion in pediatric patients was 3 grams, which was non-lethal.

Other important adverse events reported with fluoxetine overdose (single or multiple drugs) included coma, delirium, ECG abnormalities (such as QT-interval prolongation and ventricular tachycardia, including torsades de pointes-type arrhythmias), hypotension, mania, neuroleptic malignant syndrome-like events, pyrexia, stupor, and syncope.

pyrexia, stupor, and syncope. Management of Overdose — In managing overdose, the possibility of multiple drug involvement should be considered. In case of acute overdose, establish and maintain an airway and ensure adequate ventilation, which may include intubation. Induction of emesis is not recommended as the possibility of obtundation, seizures, or dystonic reactions of the head and neck following overdose may create a risk for aspiration. Gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. A specific precaution involves patients who are taking or have recently taken SYMBYAX and may have ingested excessive quantilies of a TCA (tricycilc antidepressant). In such cases, accumulation of the parent TCA and/or an active metabolite may increase the possibility of serious sequelae and extend the time needed for close medical observation.

needed for close medical observation Due to the large volume of distribution of olanzapine and fluoxetine, forced diuresis, dialysis

hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidote for either fluoxeline or olanzapine overdoes is known. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathominetic agents. Do not use epinephrine, dopamine, or other sympathomimetics with β-agonist activity, since beta stimulation may worsen hypotension in the setting of olanzapine-induced alpha blockade.

- Every 2 weeks for the next 4 weeks
- · After taking the antidepressant for 12 weeks After 12 weeks, follow your health care provider's advice about how often to come back
- · More often if problems or questions arise (see Section 3)

You should call your child's health care provider between visits if needed.

3. You Should Watch for Certain Signs If Your Child is Taking an Antidepressant Contact your child's health care provider *right away* if your child exhibits any of the following signs for the first time, or if they seem worse, or worry you, your child, or your child's teacher:

- · Thoughts about suicide or dying
- · Attempts to commit suicide
- · New or worse depression
- · New or worse anxiety · Feeling very agitated or restless
- · Panic attacks
- · Difficulty sleeping (insomnia)
- New or worse irritability
- · Acting aggressive, being angry, or violent
- Acting on dangerous impulses

pharmacist where to find more information.

- · An extreme increase in activity and talking
- Other unusual changes in behavior or mood

Never let your child stop taking an antidepressant without first talking to his or her health care provider Stopping an antidepressant suddenly can cause other symptoms.

4. There are Benefits and Risks When Using Antidepressants

Antidepressants are used to treat depression and other illnesses. Depression and other illnesses can lead to suicide. In some children and teenagers, treatment with an antidepressant increases suicidal thinking or actions. It is important to discuss all the risks of treating depression and also the risks of not treating it. You and your child should discuss all treatment choices with your health care provider, not just the use of

Other side effects can occur with antidepressants (see section below).

c® is a registered trademark of Eli Lilly and Company.

Zoloft® is a registered trademark of Pfizer Pharmaceuticals

Anafranil® is a registered trademark of Mallinckrodt Inc.

Of all the antidepressants, only fluoxetine (Prozac®) has been FDA approved to treat pediatric depression.

For obsessive compulsive disorder in children and teenagers, FDA has approved only fluoxetine (Prozac®), sertraline (Zolott®), fluvoxamine, and clomipramine (Anafranit®).

Your health care provider may suggest other antidepressants based on the past experience of your child or other family members.

Is this all I need to know if my child is being prescribed an antidepressant? No. This is a warning about the risk for suicidality. Other side effects can occur with antidepressants. Be sure to ask your health care provider to explain all the side effects of the particular drug he or she is prescribing. Also ask about drugs to avoid when taking an antidepressant. Ask your health care provider or

This Medication Guide has been approved by the US Food and Drug Administration for all antidepre

The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physician's Desk Reference (PDR)*.

Physicians: Desk Heterence (PDH). DOSAGE AND ADMINISTRATION SYMBYAX should be administered once daily in the evening, generally beginning with the 6-mg/25-mg capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of SYMBYAX has no been studied. Dosage adjustments, if indicated, can be made according to efficacy and tolerability. Antidepressant efficacy was demonstrated with SYMBYAX in a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg (see CLINICAL STUDIES). The safety of doses above 18 mg/75 mg has not been evaluated in clinical studies. Snecial Ponulations

Special Populations The starting dose of SYMBYAX 6 mg/25 mg should be used for patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of SYMBYAX (female gender, geriatric age, nonsmoking status). When

Literature revised March 3, 2006

Eli Lilly and Company Indianapolis, IN 46285

www.SYMBYAX.com

PV 5411 AMP PRINTED IN USA Copyright © 2003, 2006, Eli Lilly and Company. All rights reserved

